On NuvaRing marketing junkets in Estonia. . a, and on Merck's Ex-CEO's coming pension payment levels -- do go read them both, but here's a bit:
. . . .New CEO Ken Frazier’s compensation is much more modest than Clark’s. He made only $9.4 million last year. But Clark’s impending retirement — he turned 65 on March 7 — will likely trigger another eye-popping payout. He has accumulated pension payments of $33.3 million and deferred compensation of $15.8 million. . . .
Do go read him.
1 comment:
An atrocity that Clark and Frazier both get paid incredible amounts of money, in essence to oversee the bust up of a moderately productive company, mismanage a pipeline, and continually cut "FTEs". Its nice that Frazier can argue to keep some Remicade rights, but if he doesn't do something about resurrecting the destroyed research engine (thanks Peter), there won't be anything left to defend. The deck chair rearranging is endless and unproductive. No one with a vision is at the helm. Might as well call it Mercktanic.
Post a Comment